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Although imatinib mesylate (Novartis, Switzerland) is currently the most effective drug with low toxicity available for treating patients with chronic myeloid leukemia (CML), approximately 10-15% of early chronic phase (CP) patients will display primary or acquired cytogenetic resistance to imatinib. Even in patients who achieve a complete cytogenetic response, minimal residual disease remains detectable by sensitive PCR techniques, indicating a continued threat of relapse. A further limitation of imatinib is that it does not actually cure CML. 1 Continued therapy is required to maintain a clinical response. Allogeneic hematopoietic stem cell transplantation is still regarded as the only curative treatment for CML. Conventional myeloablative regimens have been limited by high rates of transplant-related mortality (TRM), especially in patients of advanced age or with comorbidities. A reduced-intensity conditioning (RIC) regimen has therefore been increasingly used in recent years, with an apparent reduction in early TRM. This approach relies on the post-transplant immune-mediated graft-versus-leukemia (GvL) effect, rather than on intensive pretransplant conditioning, and thus seems to be especially suitable for CML, in which the GvL effect is uniquely effective. However, relapse after RIC remains an important problem, which could be resolved by post-transplant imatinib therapy. 2 To take advantage of both the curative potential of hematopoietic stem cell transplantation and the high efficacy of targeted therapy with imatinib, our center has used an RIC regimen based on busulfan (Bu), fludarabine (Flu) and anti-thymocyte globulin (ATG), combined with pre-and post-transplant imatinib for patients with CML in the first chronic phase (CP1). The purpose of this retrospective study was to evaluate the efficacy and safety of this combination therapy in patients with CML.
From June 2005 to October 2007, twenty-eight consecutive patients with Philadelphia chromosome (Ph)-positive CML in CP1 were enrolled in this study. These included 16 male and 12 female patients with a median age of 26 years (range, 17-49 years). All of them provided signed consent. RIC allogeneic stem cell transplantations (allo-SCT) combined with pre-and postimatinib were performed. The median interval from diagnosis to transplant was 8 months (range, 4-28 months). Donors were selected on the basis of HLA-A, -B, -C, -DP, -DQ and -DR typing by the PCR-sequence specific oligonucleotide hybridization procedure. Those who donated peripheral blood stem cells (PBSCs) were injected subcutaneously with a granulocytecolony stimulating factor (Filgrastim, Kirin, Japan, 5 mg/kg/d for 5 days) before PBSC collection by leukapharesis.
The conditioning regimen included intravenous Flu 30 mg/m 2 /day (from days -10 to -5), oral Bu 4 mg/kg/day (n ¼ 4) or intravenous Bu 3.2 mg/kg/day (n ¼ 24) (from days -6 to -5), and ATG Fresenius 5 mg/kg/day (from days -4 to -1). All patients received cyclosporin (CsA), mycophenolate mofetil (MMF) and short-term methotrexate to prevent acute graft-versus-host disease (aGVHD). CsA (2.5 mg/kg/day) was started on day À7, with a target blood level of 200-300 ng/ml. The dosage was tapered during the second to third month post-transplant, according to chimeric status and evidence of graft-versus-host disease (GVHD). MMF was started orally at a dose of 500 mg/day on day þ 1 and stopped on day þ 28 in the case of related donors; however, for unrelated transplant, it was started on day þ 1, tapered from day þ 28 and withdrawn on day þ 100. Methotrexate was administered at a dose of 10 mg/day on days 1, 3 and 6. Patients who survived X100 days were monitored for chronic GVHD (cGVHD).
Imatinib was administered at a dose of 400 mg/day for 3-6 months before transplantation to reduce leukemia burden and 400-600 mg/day after transplantation to treat relapsed disease or graft failure. Prophylactic imatinib 300-400 mg/day was commenced on day þ 100 in engrafted patients to prevent relapse and was discontinued 12 months after transplantation. Cytogenetic analysis for the Philadelphia chromosome and the bcr-abl reverse transcriptase PCR test were applied at diagnosis, before transplantation and during follow-up after transplantation to detect minimal residual disease or relapse.
The Twenty-three out of the 28 patients (82.1%) treated with imatinib for 3-6 months before transplantation achieved complete hematological remission, and 14 out of 23 patients (60.8%) achieved major cytogenetic remission. After transplantation, all but the two patients who experienced primary graft failure achieved complete cytogenetic remission, and 16 patients achieved complete molecular remission (CMoR) at þ 1 month. Twenty-five of the 28 patients (89.2%) were treated with imatinib at various times after transplantation, including seven treated for relapsed disease, three for graft failure and 15 for prophylaxis. Among the seven relapsed patients, six with cytogenetic or molecular relapse achieved CMoR once again, including four receiving imatinib alone (case 1, 8, 13, 28) and two receiving imatinib plus donor lymphocyte infusion (DLI) (case 11, 19). Unfortunately, one patient with extramedullary relapse failed to respond to post-transplant imatinib therapy (case 18). The two primary graft failure patients also failed to respond and experienced disease progression (case 7, 14), whereas the secondary graft failure patient achieved CMoR on imatinib alone (case 12). Among the fifteen patients who received prophylactic imatinib to prevent relapse, only one (case 5) experienced cytogenetic relapse 1 year after transplantation, and the others achieved sustained CMoR. Three patients did not receive post-transplant imatinib, for the sake of early TRM (case 3), due to the occurence of early TRM (case 3) and extensive GVHD complicated by pancytopenia (case 4 and 10). At a median follow-up of 23 months (range, 2-42 months), the overall non-relapse mortality was 14.3% (range, 4-28 patients) and the 3-year cumulative non-relapse mortality was 15.4%. Relapse-related death occurred in one patient who died from intracalvarial granulocytic sarcoma because of extramedullary relapse 7 months post-transplant. (Table 1) The overall survival was 82.1% (range, 23-28 patients). Three-year estimated overall survival and disease-free survival were 81 and 66.7%, respectively. (Figure 1 ) Twenty-one out of 23 patients (91.3%) were in molecular remission (15 of them in first molecular remission).
Despite dramatic advances in the treatment of CML, hematopoietic stem cell transplantation remains the only curative approach able to cause a durable and complete disappearance of BCR-ABL transcripts. The standard myeloablative allo-SCT has been limited by high rates of TRM and, in contrast, RIC allo-SCT has recently yielded encouraging results with reductions in TRM. In our study, the early TRM was only 3.6% (range, 1-28 TRM). The rate seems underestimated as our study cohort was comprised of young patients; however, in another RIC trial from the European Group for Blood and Marrow Transplantation, the recipient age was proven not to affect TRM, and only CP and Flu/Bu/ATG conditioning regimen were favorable pre-transplant factors for reduction in TRM. Their TRM was also comparably low (early TRM: 3.8%). 3 Besides, the low TRM in our study can also be partially explained by a decreased incidence of severe GVHD. Only seven out of 26 (26.9%) patients developed I-II aGVHD and no patient developed III-IV aGVHD, the incidence of which was apparently lower than that reported in earlier RIC allo-SCT studies. 3 Thus, early RIC allo-SCT may be justifiably safe for CML patients in CP1.
Relapse of CML can also be a matter of concern after RIC allo-SCT. In our study, eight out of the 25 engrafted patients (32%) experienced cytogenetic (n ¼ 5), molecular (n ¼ 2) or extramedullary relapse (n ¼ 1) within 1 year after transplantation. The incidence of relapse in our patients was relatively high, but was similar to that of the European Group for Blood and Marrow Transplantation trial (relapse rate: 34.6% for CP1). 3 The increased risk of relapse might be attributed to the use of Flu, which has less anti-tumor effect per se, as recorded in other studies. 3 A high-leukemia burden also seems to be associated with relapse after transplantation, and, therefore, most patients in our study received pre-transplant imatinib to improve their remission status. Unexpectedly, there was no association between cytogenetic remission achieved before transplantation and relapse risk (28.6 vs 36.4%, P ¼ 0.678). Nevertheless, this observation needs to be interpreted with caution because it is based on a very small number of patients.
The increased risk of relapse after RIC allo-SCT requires the development of an optimal management strategy. Efforts to treat relapse after transplantation have focused on the restoration of a GvL effect using DLI, as initially reported by Kolb. However, the possible side effects, such as life-threatening GVHD and pancytopenia, lead to a high-risk of TRM and hamper its use in the early post-transplant period. The potential side effects of DLI make imatinib an attractive therapeutic alternative for CML patients with early relapse after RIC allo-SCT, especially those with molecular relapse. Our study confirmed that the majority of patients relapsing after transplantation could successfully achieve CMoR with imatinib. The drug also postponed the requirement for DLI and synergized with DLI, as observed in two patients in our study as well as in a recently published study. 2 The action of imatinib could have been solely because of its inherent antileukemic properties, but it is also possible that the reduction in leukemia burden caused by imatinib created a window of opportunity for GvL effects. In addition to being an effective salvage therapy for relapsed CML, imatinib also showed some prophylactic value. With a median 20.5-month follow-up (range, 13-41 months) for the fifteen patients treated with prophylactic imatinib, only one experienced cytogenetic relapse 1 year after transplantation, indicating the protective effect of this drug.
A controversy regarding the immunological effects of imatinib exists to date. An in vitro experiment showed that imatinib inhibited the activation and proliferation of normal T lymphocytes. 4 However, the function of immunosuppressive CD4 þ CD25 þ regulatory T cells was also hampered in a similar manner, indicating that clinical administration of imatinib did not necessarily result in a reduction of the GvL effect. 5 The inhibitory GvL effect of imatinib could not be concluded from our study either. Conversely, several studies suggested that imatinib could significantly enhance antigen presentation by antigen-presenting cells, overcome tumor-induced CD4 þ T-cell tolerance and thereby facilitate the GvL activity. 6 It is currently believed that leukemic stem cells cannot be depleted by imatinib alone, 1 and drug discontinuation usually leads to disease relapse. However, when combined with allogeneic hematopoietic stem cell transplantation, the maintenance of a durable response seems feasible, even after the discontinuation of imatinib, hence potentially providing a definite cure for CML. Our study supported this possibility, with 21 patients surviving and remaining in CMoR after a maximum follow-up of 30 months after withdrawal of imatinib.
In summary, RIC allo-SCT combined with imatinib was well tolerated in CML patients with a low-risk of GVHD. Imatinib changed the kinetics of disease relapse after RIC allo-SCT and the anti-leukemic immunological function of RIC could provide a definite cure for CML. This combination needs to be further investigated in future prospective trials. Here, we applied the methylation-specific multiplex ligationdependent probe amplification (MS-MLPA) assay to find out whether the methylation status of a defined set of tumor suppressor genes (TSG) allows for the discrimination of T-ALL from NK-cell-derived cell lines. 3 Promoter hypermethylation of tumor suppressor genes is often seen in malignant diseases and, according to the widely held view, contributes to the rise of malignant cell clones by keeping the tumor suppressors at a low level. 4 Specific profiles of hypermethylated CpG islands have been described, which are unique for different neoplasias. [5] [6] [7] More recently, gene methylation patterns have also been used to identify lymphomatous entities. 8, 9 In this study, MS-MLPA assay showed that the promoter of one of the twenty-four tumor suppressor genes that was analyzedF Death-associated protein kinase 1 (DAPK1)Fwas typically methylated in NK and NK/T cell lines, but not in T-ALL cell lines (Table 1) . DAPK1 is a Ca 2 þ /calmodulin-dependent serinethreonine kinase and acts as a positive mediator of interferon-g-, tumor necrosis factor-a-and FAS-induced apoptosis.
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Methylation-specific PCR of bisulfite-converted DNA confirmed the MS-MLPA assay results suggesting that the methylation status of DAPK1 might help to differentiate between NK-and NK/T cells on the one hand and T cells on the other (Figure 1, Table 1 ). However, not all T-cells show the unmethylated form of DAPK1: cell lines KARPAS-299, L-82 Table 1 DAPK1 methylation and expression in NK-NK/T and T-cell lines 
